Search

Displaying results 1921 - 1930 of 10000 in total
  1. Drug

    AN-2718

    go.drugbank.com/drugs/DB12810
    Investigational

    An2718 has been used in trials studying Tinea Pedis.

  2. Drug

    Gliquidone

    go.drugbank.com/drugs/DB01251
    Approved

    Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. … This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

    International brands: Ka Rui LinCategories: Drugs Used in Diabetes, Cytochrome P-450 Substrates
  3. Drug

    AVN-944

    go.drugbank.com/drugs/DB05500
    Investigational

    AVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism … AVN944 has been associated with cancer cell death in clinical trials. It is being investigated for the treatment of patients with advanced hematologic malignancies.

  4. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). … [L41960] In December 2025, the FDA expanded Berotralstat pediatric use with approval of an oral pellet formulation for prophylaxis in children with HAE aged 2 and older.[L54793,L54798]

    Categories: Drugs Used in Hereditary Angioedema, P-glycoprotein inhibitorsSynonyms: 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide, (+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride
  5. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    Its use is not recommended in patients with type 1 diabetes since it may increase their risk of diabetic ketoacidosis.[L44758] … [A256413] SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney.

    Synonyms: D-glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1s)-, (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triolCategories: Drugs Used in Diabetes, P-glycoprotein substrates
  6. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc. … Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic [faropenem].

    Categories: Heterocyclic Compounds, 2-Ring
  7. Drug

    Zofenopril

    go.drugbank.com/drugs/DB13166
    ApprovedInvestigational

    Zofenopril is employed as both a cardioprotective and anti-hypertensive agent. It is an angiotensin-converting enzyme (ACE) inhibitor.

    Mixtures: ZOFENOPRIL E IDROCLOROTIAZIDE EG, ZOFENOPRIL E IDROCLOROTIAZIDE MYLANCategories: Agents Acting on the Renin-Angiotensin System
  8. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural elements of [irbesartan], an AT<sub>1</sub>R antagonist, and biphenylsulfonamide, an ET<sub … Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub

    Categories: Angiotensin II Type 1 Receptor Blockers, Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA)
  9. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    [L31178] Although not the first sGC stimulator to be granted FDA approval ([riociguat] was approved in 2013 for use in pulmonary hypertension),[L3955] vericiguat is unique amongst its peers in that modifications … Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations.

    Categories: Vasodilators Used in Cardiac Diseases, P-glycoprotein substratesProducts: VERQUVO® 5MG TABLETAS RECUBIERTAS, VERQUVO® 10MG TABLETAS RECUBIERTAS
  10. Drug

    Iopromide

    go.drugbank.com/drugs/DB09156
    Approved

    it is still deemed to have a favorable safety profile, with only 0.7% of patients in a 2 years study experiencing adverse events. … Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration.

    Categories: Compounds used in a research, industrial, or household setting, X-Ray Contrast ActivitySynonyms: N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylisophthalamide